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Exploring the bowels of DNA methylation
Recent studies of mice lacking methyltransferase, and of genes that
modify cancer susceptibility, have shed light on the long-standing
problem of how DNA methylation affects carcinogenesis.
The role DNA methylation is thought to have in cancer
has become increasingly complex. In the late 1970s and
early 1980s, it was shown that methylation of CpG sites
in DNA can exert a negative influence on gene expres-
sion. Treatment of fibroblastic 10T¼2 cells in culture with
demethylating agents, such as 5-azacytidine, facilitated
the emergence of novel muscle or brain-related cell
types, presumably by removing methyl groups from
developmentally important genes, allowing their expres-
sion [1]. One of the genes responsible for the myogenesis
programme, MyoD, was subsequently found to be methy-
lated in the original 10T2 cells, but became demethy-
lated (and expressed) in their muscle progeny. Relevance
to cancer development was suggested by the observation
that tumour cells tend to have hypomethylated DNA [2],
and consequently begin to express genes that could con-
fer a growth advantage. Obligingly, some genes that are
hypomethylated in cancers turned out to be oncogenes
[3], completing a satisfying hypothetical loop (Fig. la).
This concept gained further support with the observa-
tion that carcinogenic alkylating agents can induce DNA
hypomethylation, in addition to their known mutagenic
effects, possibly by preventing cytosine methylation at
sites adjacent to 06 -alkylguanosine residues [4]. The
conclusion to be drawn from these studies was that
hypomethylation of tumour DNA would allow uncon-
trolled or aberrant oncogene expression, with obvious
advantages for tumour cell growth.
The problems inherent in this simplistic interpretation
became apparent with the demonstration that some
tumour cell lines have very high levels of the enzyme
DNA (cytosine-5) methyltransferase (CMT), which indu-
ces methylation of CpG residues [5]. Methylated regions
were then found in chromosome locations known to
harbour tumour suppressor genes [6], leading to another
potential role for methylation in cancer: the silencing of
growth-suppressing genes (Fig. lb). An additional mech-
anism by which methylation can influence tumorigenesis
lies in the intrinsic mutability of 5-methylcytosine
residues. The CpG dinucleotide is relatively rare in the
mammalian genome, presumably because methylation of
cytosine induces instability, by leading to its deamination
to form thymidine. During subsequent DNA replica-
tion, the G:T mismatch, if not properly repaired, gives
rise to an A:T base-pair at the original site [7]. It can
therefore be argued that such 'endogenous' methylation
events are in themselves potentially mutagenic, and con-
tribute directly to genetic (Fig. c), rather than epigenetic
(Fig. la,b), mechanisms of cancer.
In support of this interpretation are the following obser-
vations. First, CMT is mutagenic in assays in vitro,
although this may involve mechanisms other than spon-
taneous deamination of 5-methylcytosine residues. Sec-
ondly, mutations in the p53 tumour suppressor gene,
which occur frequently in many types of human cancer,
are more often seen at CpG sites than would be expected
from the frequency of such sites within the gene [7,8].
The frequency of transition mutations at CpG sites is par-
ticularly high in colorectal tumours [8], leading to specula-
tion about the molecular mechanisms underlying the vari-
able spectrum of p53 mutations in tumours arising in
different tissues. Lung tumours from smokers, for example,
frequently exhibit transversion mutations in p53, in accord
with the expected consequence of exposure to polycycic
aromatic hydrocarbons, whereas lung tumours from non-
smokers, and colorectal tumours, have a much higher fre-
quency of G--A transition mutations (reviewed in [7,8]).
Fig. 1. Possible roles for altered methylation in cancer.
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All of this incriminating evidence points the finger firmly
at endogenous methylation of CpG sites as a primary
perpetrator of genetic or epigenetic alterations that lead
to colon cancer and to some other tumour types. How-
ever, the mechanisms by which methylation influences
carcinogenesis are being hotly debated. The three possi-
bilities outlined in Figure 1 are not mutually exclusive,
and indeed all three may be operative at different stages
of tumour development. Carcinogenesis in the human
colon and in animal model systems is a multistep process,
and although demethylation has been detected in specific
genes at relatively early stages of tumour development, its
functional significance is far from clear. The first steps
towards the resolution of these important questions have
been made in a recent paper describing the effects
on tumour development of targeted disruption of the
CMT gene [9].
In a previous report, Li et al. [10] had shown that CMTis
essential for normal mouse development, as homozygous
null mice died at mid-gestation. The precise reasons for
lethality have not been established, but are presumably
related to the effects of methylation on tissue-specific
gene expression or on differential imprinting of parental
alleles (for review, see [11]). Embryonic lethality is of
course not a helpful phenotype for studies of tumour
development, which is essentially an adult phenomenon.
Laird et al. [9] cleverly overcame this problem, however,
by using mice heterozygous for the inactive allele, which
express half normal CMT levels. DNA methylation was
further reduced by treatment of the animals with 5-azacy-
tidine. This combined approach led to a substantial inhi-
bition of DNA methylation with no obvious impairment
of viability.
In order to assess the effects on tumour formation, the
methylation-deficient animals were crossed with the well-
known 'Min' mice, which spontaneously develop multi-
ple intestinal neoplasia as a consequence of a germline
mutation in the mouse homologue of the human APC
gene [12]. The question asked by the authors was: does
lack of genomic methylation increase tumour yield by
allowing aberrant proto-oncogene expression (Fig. la), or
does it inhibit tumorigenesis, either due to elevated
expression of tumour suppressor genes (Fig. lb) or to lack
of mutational events in critical target genes (Fig. lc)? The
result was very convincing: reduced methylation almost
completely suppressed tumour formation. This can be
reconciled with the interpretations in Figure lb or c, but
not with a role for methylation in the control of proto-
oncogene expression (Fig. la). Of the two possible mech-
anisms compatible with the data, Laird et al. [9] came
down firmly in favour of a genetic or mutational role for
methyltransferase in colon cancer development, rather
than the epigenetic silencing of tumour suppressor genes .
How justified is this conclusion? One argument against
the 'epigenetic silencing' possibility (Fig. lb) comes from
studies designed to test whether methylation could inac-
tivate the p53 tumour suppressor gene in a model system
in vitro. It was found that, while p53 was indeed inacti-
vated during transformation, this was never associated
with methylation of the CpG-rich 'island' within the
gene ([13]; A Bird, personal communication). It could
therefore be argued that, if p53 silencing by methylation
does not take place in this ideal system, it is unlikely to
be an important mechanism in vivo. Nevertheless, other
interpretations are possible. It has been suggested that
DNA methylation is an ancestral mechanism for neutral-
izing potentially damaging DNA elements in the genome
[14]. The p53 gene may have evolved some protective
mechanism that prevents its silencing by methylation, as
this could increase genomic instability.
An additional factor that has to be taken into account is
the continuous clonal selection that takes place in an
evolving tumour cell population. In this situation, the
control of methylation may be aberrant, rather than a
quantitative deficiency, as seen in the CMT-knockout
mice. Although local hypermethylation may not occur
frequently during tumour development, if it fortuitously
leads to silencing of a growth-suppressor gene, it should
be strongly selected In the experiments described by
Laird et al. [9], the condition of low methylation levels is
imposed from the outset, and any aspiring tumour cells
have less flexibility in selecting the appropriate combina-
tions of expressed (demethylated) or silenced (methy-
lated) genes. The power of selection is graphically
illustrated by the experiments performed by Antequera
et al. [15], which showed that many genes that may be
detrimental to cell growth and proliferation in vitro are
silenced by methylation.
A number of lines of evidence suggest that such changes
in the control of gene expression by methylation are
indeed important in carcinogenesis. The strongest of these
comes from studies of altered patterns of genetic imprint-
ing in human embryonal tumours (Fig. 2). Imprinting
results in differential expression of the maternal and pater-
nal alleles of critical growth-controlling genes [16]. The
gene for insulin-like growth factor 2 (Igf-2) is located
within an imprinted region of mouse chromosome 7 and
human chromosome 11lp, and is normally expressed only
from the paternal allele [17]. In certain human embryonal
tumours, loss of imprinting occurs [18,19], leading to
overexpression of Igf-2 from both alleles. An alternative
genetic mechanism with the same consequence is loss
of heterozygosity at ll11p15, as is seen in a proportion
of Wilms' tumours [20]. In these cases, the maternal
(silenced) allele is preferentially lost, and the paternal allele
duplicated, a genetic event which simultaneously causes
increased expression of Igf-2 [21] and loss of the expressed
allele of the oppositely imprinted H19 gene [22] (Fig. 2a).
H19 encodes an untranslated, maternally expressed RNA,
and has been shown to have tumour-suppressive proper-
ties [23]. It has been suggested that paternal-specific
methylation of H19, in addition to silencing the gene,
allows adjacent enhancer sequences to interact with regu-
latory elements in the Igf-2 gene [24]. This elegant expla-
nation for simultaneous (but opposing) effects on the
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Fig. 2. Altered methylation in embryonic or adult tumours.
expression of both genes is supported both by analysis of
the expression status of H19 and Igf-2 in the DNA
methyltransferase knockout mice [25] and, more recently,
by inactivation of the H19 gene itself [24]. Both sets of
experiments lead to the conclusion that if H19 is
expressed, suppression of Igf-2 occurs, even though it is
located at a distance of about 100 kilobases.
Could induced expression by demethylation of a poten-
tial tumour suppressor gene such as H19, with concomi-
tant repression of Igf-2, account for lack of colon polyp
development in Min/CMT heterozygous mice? It is
noteworthy that the effects of the 5-azacytidine on polyp
formation are seen only if it is administered soon after
birth [9] and are not observed in young adults. Hetero-
zygosity at the CMT locus, together with administration
of 5-azacytidine, could cause repression of the early
(embryonic?) precursor cells in Min mice, which give rise
to polyps, due to either overexpression of H19 or lack of
Igf-2. A specific role for Igf-2 or H19 in classical 'adult'
tumours has, to my knowledge, not yet been demon-
strated. It is possible that the action of Igf-2 is more
important for cells initiated towards tumour formation
early in development (including those arising from
germline mutations) than for cells in which initiating
mutations occur later in life.
Methylation of another set of genes that are not neces-
sarily imprinted during development has also been
implicated in carcinogenesis (Fig. 2b). Such genes
include the von Hippel-Lindau (VHL) gene, which is
mutated frequently in renal cell carcinomas but can also
be silenced by methylation [26], the glutathione-S-trans-
ferase gene, which is involved in DNA damage preven-
tion [27], and the retinoblastoma (Rb) gene [6]. Other
candidates for methylation-mediated silencing lie in the
pathways by which Rb induces cell-cycle arrest. The
pl6/INK4a/Mts-l tumour suppressor gene on human
chromosome 9p is involved in the control of cell-cycle
progression through the G1/S-phase boundary, by influ-
encing the phosphorylation state of the retinoblastoma
protein [28], and it undergoes loss of heterozygosity at a
relatively early stage of squamous tumour development
- but although deletions of this gene occur frequently
in cell lines, very few mutations have been detected in
primary tumours [29]. Partial or complete silencing of
genes such as p16 during the early stages of tumour
growth by the mechanisms shown in Figure 2b would
appear to warrant further investigation.
It may therefore be premature to discount completely
the epigenetic explanations in favour of the mutation
hypothesis. If a mutational mechanism is indeed required
at the first steps of tumour evolution, as would be
inferred from the requirement for early azacytidine treat-
ment in the protocol of Laird et al. [9], one of the most
likely targets would be the wild-type allele of APC itself,
which is generally inactivated in adenomas. However,
Laird et al. demonstrated that the wild-type allele is lost
at the same frequency during adenoma development in
Min mice and in azacytidine-treated Min/CMT het-
erozygotes, and is therefore not a candidate for mutation
by a methylation-mediated mechanism.
The experiments carried out by Laird et al. [9] only
addressed early stages of colon carcinogenesis and did not
investigate the issue of progression from polyps to car-
cinomas. There is compelling evidence, largely based on
analysis of germline and somatic p5 3 mutations, that
methylation at CpG sites is a potentially mutational event.
However, mutations in this gene in the colon are rarely
found in adenomas, and are much more frequent in carci-
nomas [8], suggesting that methylation-induced mutations
are more relevant to tumour progression than to initiation.
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Finally, dramatic progress has recently been made in
elucidating a completely independent pathway for sup-
pression of adenoma formation in Min mice. Certain
mouse strains have modifier genes which exert a strong
inhibitory effect on polyp development. A locus dubbed
Mom-1 (modifier of Min) was localized to the distal
region of chromosome 4 and accounts for 50 % of the
variation between susceptible and resistant mouse strains
[30]. Interest in such modifier loci has increased substan-
tially with the realization that their identification could
provide unique information on how evolution has come
up with different mechanisms for controlling tumour
growth, with obvious implications for novel approaches
to tumour therapy.
A strong candidate for the Mom- 1 locus on chromosome
4 has now been cloned and shown to encode a secreted
phospholipase A2 [31]. Min-l-susceptible strains carry
mutations which probably eliminate phospholipase A2
activity, whereas resistant strains produce the mRNA
and, presumably (although not yet formally demon-
strated), biologically active protein. It is unlikely that the
results obtained by Laird et al. [9] can be explained by
altered expression of the Mom-1 modifier locus, as both
of the parental strains they used carry the inactive phos-
pholipase A2 allele. Nevertheless, epigenetic modifica-
tion of the expression of this or other modifier genes
could contribute to overall cancer susceptibility in other
strain combinations or in humans.
The mechanism by which phospholipase A2 acts to
suppress adenoma formation is unclear, but the authors
speculate that its involvement in digestion of dietary fatty
acids may play an important role. Alternatively, tumour
prevention may be achieved through some disturbance of
prostaglandin synthesis. It is of interest that anti-inflam-
matory agents have already been shown to inhibit polyp
formation in humans [32]. Thus, the genetic approach of
cloning modifier genes has converged with other avenues
of research to identify prostaglandin synthesis, control of
inflammation, and fatty acid metabolism as important
factors in colon cancer prevention. These results under-
line the potential importance of mouse models in the
identification of modifier or tumour resistance genes
[33], which may lead to novel forms of cancer control.
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